Although BTK and PLCγ2 mutations have been found to be associated with ibrutinib resistance in a fair percentage of CLL patients, no information on resistance mechanisms is available in patients lacking these mutations. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.